Therapy after cyclin‐dependent kinase inhibition in metastatic hormone receptor‐positive breast cancer: Resistance mechanisms and novel treatment strategies-Reference-Cited by-同舟云学术

Therapy after cyclin‐dependent kinase inhibition in metastatic hormone receptor‐positive breast cancer: Resistance mechanisms and novel treatment strategies

Published:2020-05-19 Issue:15 Volume:126 Page:3400-3416
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Sharifi Marina N.¹²^ORCID,Anandan Apoorva³,Grogan Patrick¹²,O’Regan Ruth M.¹^ORCID

Affiliation:

1. Division of Hematology and Oncology Department of Medicine University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA

2. Internal Medicine Pathway for Academic Career Training (IMPACT) Physician Scientist Program Department of Medicine University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA

3. Internal Medicine Residency Program Department of Medicine University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32931

Reference64 articles.

1. Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States

2. The Hallmarks of Cancer

3. Cell cycle proteins as promising targets in cancer therapy

4. CDK inhibitors: positive and negative regulators of G1-phase progression

5. The history and future of targeting cyclin-dependent kinases in cancer therapy

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is the Androgen Receptor a Viable Target in Triple Negative Breast Cancer in 5 Years?;Clinical Breast Cancer;2023-12

2. Resistance to abemaciclib is associated with increased metastatic potential and lysosomal protein deregulation in breast cancer cells;Molecular Carcinogenesis;2023-10-11

3. Resistance to abemaciclib is associated with increased metastatic potential and lysosomal protein deregulation in breast cancer cells;2023-04-18

4. Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer—A Review of the Literature;Diagnostics;2023-03-05

5. BAP18 facilitates CTCF-mediated chromatin accessible to regulate enhancer activity in breast cancer;Cell Death & Differentiation;2023-02-24